TCBP

TC BioPharm (Holdings) PLC Sponsored ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cbiopharm.com
Employees(FY) 60
ISIN US87807D4007

Performance

-13.29%

1W

-34.74%

1M

+31.79%

3M

-88.3%

6M

-60.88%

YTD

-93.33%

1Y

Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Advanced Technical Analysis

Technical Analysis of TCBP 2024-05-03

Overview:

In analyzing the technical indicators for TCBP over the last 5 days, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide your inves...

See more ...

Recent News & Updates

2024-05-06 01:01
TC BioPharm Announces Exercise of Warrants for 3.1 Million Gross Proceeds(Prnewswire)
2024-05-05 23:32
ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range?(Investorplace)
2024-05-05 23:07
Warren Buffett Just Gave Up on Paramount (PARA) Stock(Investorplace)
2024-05-05 22:37
Why Is TC Biopharm (TCBP) Stock Up 51% Today?(Investorplace)
2024-05-05 20:30
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies(Prnewswire)
2024-04-03 22:37
Why Is TC Biopharm (TCBP) Stock Up 78% Today?(Investorplace)
2024-04-03 20:32
TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies(Prnewswire)
2024-04-01 20:30
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process(Prnewswire)
2024-03-18 20:30
TCBP Adjourns General Meeting Until a Later Date(Prnewswire)
2024-03-17 20:30
TCBP Announces Exercise of Series D Warrants For Cash(Prnewswire)
2024-02-29 19:30
Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated 'The Big Biz Show'(Prnewswire)
2024-02-26 19:30
TCBP Announces Shareholder Update Call on March 5th 2024(Yahoo Finance)
2024-02-21 20:32
TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial(Prnewswire)
2024-02-14 19:30
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe(Prnewswire)
2024-02-13 19:30
TCBP Provides Shareholder Update and Highlights Upcoming Milestones(Yahoo Finance)
2024-01-28 19:30
TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'(Prnewswire)
2024-01-17 19:30
TC BioPharm to Present at the Sequire Investor Summit(Prnewswire)
2024-01-03 19:30
TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement(Prnewswire)
2024-01-02 19:30
TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies(Prnewswire)
2023-12-21 19:30
TC BioPharm Announces Closing of $3.5 Million Public Offering(Prnewswire)
2023-12-18 19:00
TC BioPharm Announces Pricing of $3.5 Million Public Offering(Prnewswire)
2023-12-17 22:15
TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D(Prnewswire)
2023-12-12 17:30
TC BioPharm Announces Plan to Implement ADS Ratio Change(Prnewswire)
2023-11-27 22:05
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug(Yahoo Finance)
2023-11-26 19:45
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia(Prnewswire)
2023-11-13 21:00
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results(Prnewswire)
2023-11-02 01:30
TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials(Prnewswire)
2023-10-24 20:00
TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements(Prnewswire)
2023-10-23 20:45
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments(Prnewswire)
2023-10-22 20:00
TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML(Yahoo Finance)

Page 1 of 3

previousnext